Daraxonrasib Demonstrates Tumor Reduction in NSCLC in Early Study

The RAS‑targeting drug daraxonrasib (brand name RasongQ), recently approved in the United States for the treatment of progressive pancreatic cancer, has shown early efficacy in lung cancer. In a small clinical study of patients with non‑small cell lung cancer (NSCLC), more than 30% experienced tumor reduction. The findings were published on 2 May in the New England Journal of Medicine. Researchers describe daraxonrasib as a “molecular glue” that binds to mutant RAS proteins, a target historically considered undruggable, and note that it previously doubled survival in pancreatic cancer patients.